Insight Molecular Diagnostics
IMDX
56 hedge funds and large institutions have $39.9M invested in Insight Molecular Diagnostics in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 9 closing their positions.
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
4% more funds holding
Funds holding: 54 → 56 (+2)
0.29% more ownership
Funds ownership: 1.54% → 1.83% (+0.29%)
0% more capital invested
Capital invested by funds: $39.8M → $39.9M (+$108K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$5.89M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$345K |
| 3 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
+$331K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$197K |
| 5 |
DAM
Doheny Asset Management
Los Angeles,
California
|
+$164K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$550K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$474K |
| 3 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$472K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$214K |
| 5 |
Jane Street
New York
|
-$178K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $2K | -$10.5K | -266 | -83% |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| $2K | +$1.49K | +38 | +760% |
|
|
MAM
53
Meeder Asset Management
Dublin,
Ohio
| $2K | +$1.85K | +47 | New |
|
54
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | – | – | – |
|
|
MS
55
Maven Securities
St Helier,
Jersey
| – | -$550K | -10,776 | Closed |
|
|
SSA
56
Schonfeld Strategic Advisors
New York
| – | -$474K | -9,525 | Closed |
|
|
MHP
57
Manatuck Hill Partners
Westport,
Connecticut
| – | -$472K | -9,480 | Closed |
|
|
58
Jane Street
New York
| – | -$178K | -3,567 | Closed |
|
|
AG
59
Algert Global
San Francisco,
California
| – | -$90K | -1,808 | Closed |
|
|
FAM
60
Fred Alger Management
New York
| – | -$50K | -1,000 | Closed |
|
61
Citadel Advisors
Miami,
Florida
| – | -$38K | -757 | Closed |
|
|
OAM
62
Oxford Asset Management
Oxford,
United Kingdom
| – | -$33K | -665 | Closed |
|
IMDX Hedge Fund Activity: Q3 2019 in Review
56 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2019, worth a combined $39.9M — up 0.27% from $39.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new IMDX positions and 9 closed out — a net gain of 3 holders — while 18 added to existing stakes and 16 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $5.89M. The largest seller was Maven Securities, exiting entirely with an estimated $550K sold.
- 56 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2019, up from 54 in Q2 2019.
- Funds reported $39.9M of Insight Molecular Diagnostics stock for Q3 2019, up 0.27% quarter-over-quarter.
- 12 funds opened new Insight Molecular Diagnostics positions in Q3 2019 and 9 closed out, a net change of +3 holders.
- The largest Insight Molecular Diagnostics buyer in Q3 2019 was Broadwood Capital, an estimated $5.89M added.
- The largest Insight Molecular Diagnostics seller in Q3 2019 was Maven Securities, an estimated $550K sold.
Based on aggregated 13F filings for Q3 2019.